IOVE DVME, PLMO, COTE, EDWY, OPGX, OTCPicks.com Stocks to Watch for Thursday, October 22nd

Our Stocks to Watch tomorrow include Diverse Media Group Inc. (OTC: DVME), Pulmo BioTech Inc. (OTCBB: PLMO), Coates International Ltd. (OTCBB: COTE), eDoorways Corp. (OTC: EDWY), Optigenex Inc. (OTC: OPGX) and Accredited Business Consolidators Corp. (OTC: IOVE).

DIVERSE MEDIA GROUP INCORPORATED (OTC: DVME)

"Up 44.44% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/DVME.php 

Diverse Media Group, Inc. (OTC: DVME) is an entertainment company that aggregates expertise across all aspects of the media industry. Diverse Media Group has at its core the established 27-year history of its wholly owned subsidiary, Diverse Talent Group. Diverse Talent Group is now the 10th largest Hollywood agency offering talent and literary representation in commercials, episodic television, cable programming and motion pictures. The company has the ability to create programming, foster distribution and represent talented individuals to fuel a new digital age of content generation. The parent company also includes the subsidiary Talent Quest America, Inc., which identifies new and rising talent representing the future of the Hollywood entertainment community.

DVME News:

September 28 - Network Talks Underway to Develop 'Momo' into Weekly TV Series Title is Part of Diverse Media Group, Inc. Option Agreement with Elio Pictures

“Momo” executive producers Dimitri Logothetis and Nicholas Celozzi have announced that talks are underway with networks in the U.S. and Canada to develop the project as a weekly series for television. “Momo” is one of six titles for which Diverse Media Group, Inc. (OTC: DVME) has optioned to purchase a 30% interest from Elio Pictures, Ltd.

Diverse Media Group CEO Chris Nassif calls the development “a huge step forward in our company’s transition to a complete entertainment and media services provider.”

Logothetis and Celozzi have been working for seven years on the life story of infamous mob boss Sam Giancana. After securing the exclusive story rights from Francine Giancana to her father’s life story, they originally set the project up at Warner Bros. and Turner as a mini-series. Logothetis calculates development costs to date at $75,000. With the success of the 60's-based AMC series “Mad Men,” they decided that “Momo” could also satisfy weekly audience interest in that period of Americana. Giancana was born in 1908 and killed in 1974.

Celozzi describes the series as real-life “Sopranos” meets “The Gangster Chronicles.” Sam Giancana was a very compelling personality. As a family man, Sam lost his wife to a rheumatic heart disease, raised three daughters, supported an extended family and was one of the most powerful men of the twentieth century. Through union ties Giancana helped swing the Illinois vote during the Kennedy/Nixon election. He was the first mobster to claim his rights to the Fifth Amendment in front of live television cameras while questioned by Bobby Kennedy during the McClellan committee hearings. Sam had a long-standing friendship with Frank Sinatra, the leader of the so called “Rat Pack,” who played in Chicago nightclubs run by Giancana.

The other Elio Pictures titles optioned by Diverse Media Group include “The Lost Angel” (2005) with Judd Nelson and Celozzi, “Framed by Seduction” (2004) starring Robert Patrick, “Nightmare Boulevard” (2004) starring Claudia Christian and Corbin Bernsen, “7-10 Split” (2007) featuring Tara Reid and Rachel Hunter, and “Senior Skip Day” (2008) with Lea Thompson and Norm MacDonald.

The option is being purchased with 25 million shares of Diverse Media Group restricted common stock, valued at $50,000. The Company has until March 30, 2010, to exercise its option for a cash price of an additional $400,000.

PULMO BIOTECH INCORPORATED (OTCBB: PLMO)

"Up 166.67% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/PLMO.php

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.

PLMO News:

October 21 - Pulmo BioTech Inc. Announces Further Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind™ to the European Market

Pulmo BioTech Inc. (OTCBB: PLMO) (Frankfort Borse: PBO) has announced has announced further details of its non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. to license its Pulmonary Vascular Diagnostic Product Candidate PulmoBind™ development work, clinical trials and ultimately, commercialization in the European market.

"Biotechnology Consulting Poland will license the technology of PulmoBind™ from Pulmo BioTech pursuant to a License Agreement expected to be entered into before the end of 2009. This will enable Biotechnology Consulting Poland to carry out Phase I trials in Europe starting in early 2010. Once these safety and efficacy trials are completed and if approval has been granted by the European Regulatory Authority it is intended that Biotechnology Consulting Poland will immediately commence Phase II/III trials for PulmoBind™ against the conditions of pulmonary hypertension and pulmonary embolism. Pursuant to the License Agreement, Biotechnology Consulting Poland will ultimately be responsible for the commercialization of PulmoBind™ across the whole of the European Union and the European Economic Area. It is contemplated that the License Agreement will have an initial term of six years, with an extension clause, and during this period Pulmo BioTech will provide all of the technical information and resources necessary to enable Biotechnology Consulting Poland to successfully complete all of its European trials work. By utilizing the technical and commercial skills of Biotechnology Consulting Poland, Pulmo BioTech will have European trials of PulmoBind™ in tandem with the work in North America, which will permit Pulmo BioTech to complete trials and begin commercialization in parallel across these two continents." - Garry McCann, CEO Pulmo BioTech Inc.

ABOUT PULMOSCIENCE INC.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind™.

PulmoScience was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind™ Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.

ABOUT PULMOBIND™

PulmoBind™ uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external Gamma Camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. PulmoScience is currently undertaking Regulatory Approval for Phase I Human Trials, and while subsequent results from additional tests might not corroborate the current results, PulmoScience believes that PulmoBind™ has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind™ will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind™ could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

ABOUT BIOTECHNOLOGY CONSULTING POLAND SP. Z.O.O.

BioTechnology Consulting Poland Sp. z.o.o. is a Polish based company which has been set up to enable the rapid approval of products developed outside the Euro Zone in the European market.

Pursuant to the License Agreement contemplated by the LOI, BioTechnology Consulting Poland will license IP from Pulmo BioTech to enable it to rapidly carry out Phase Trials and ultimately commercialize PulmoBind™ across the whole of the European Union and European Economic Area.

BioTechnology Consulting Poland counts amongst its key staff, professionals in the areas of medical project management, new business start-up and growth, and medical Phase Trials. BioTechnology Consulting Poland has links with key Polish medical facilities, CROs and Pharmaceutical companies.

COATES INTERNATIONAL LIMITED (OTCBB: COTE)

"Up 64.10% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/COTE.php

Coates has been developing over a period of more than 15 years a patented spherical rotary valve CSRV Internal Combustion Engine invented by George J. Coates and his son Gregory. The CSRV system is adaptable to combustion engines of many types. This technology is currently adapted to a number of practical applications, including industrial generators powered by engines incorporating the CSRV technology and designed to operate on flare-off gas from oil wells, landfill gas and raw natural gas. The Company is actively engaged in preparing for the commencement of manufacturing of products utilizing this technology.

COTE News:

October 21 - Coates International Ltd. Signs Bond Issue Deal for $300,000,000 USD

Coates International, Ltd. (OTCBB: COTE) (the "Company"). After many months of intense negotiation the company on October 20, signed a Joint Venture (Entity) to process a bond offering, that the net proceeds will be $300,000,000 USD for the company. This funding is specifically for the start up of two manufacturing and production facilities, one in Miami, Oklahoma and the other in New Jersey not far from the existing Coates world headquarters facility in Wall Township, New Jersey. This transaction was initiated by George J. Coates, President, CEO and Barry Kaye, CFO.

George J. Coates, President and CEO, stated this is a very exciting and important prospect for our company. These funds will facilitate large scale manufacturing of our Coates CSRV Industrial Electric Power Natural Gas Generators and the 18 Wheeler Tractor Trailer Diesel CSRV Engines, of which the company has large orders for both of these products.

The Company's large scale manufacturing plans will require the creation of thousands of new quality permanent jobs and substantial capital expenditures that we believe will help boost the U.S. economy. Our world-wide patented Coates Spherical Rotary Valve (CSRV) System technology lowers the consumption of fossil fuels and will reduce the U.S. dependency on imported foreign oil, while lowering harmful exhaust emissions that are released into our atmosphere.

We have previously entered into an agreement with Oklahoma which would enable us to qualify for a package of business and tax incentives by hiring plant workers and making capital expenditures in the state that could amount to as much as approximately $750 million. Barry Kaye, Chief Financial Officer, stated: "The business and tax incentives in Oklahoma, coupled with the opportunity to utilize our substantial net operation loss carryforwards to offset income taxes will give us an additional advantage by improving our profitably in the early stages of our manufacturing phase of operations."

EDOORWAYS CORPORATION (OTCBB: EDWY)

"Up 23.02% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/EDWY.php

eDOORWAYS Corporation is developing a lifestyle information/entertainment platform for visually-oriented Web surfing community. Its eDOORWAYS portal is a Web-based personal lifestyle information enhancement and problem solving gateway, lifestyle information source, and online business-to-consumer marketplace. The company was incorporated in 1988 as Technicraft Financial, Ltd. and changed its name to LBM-US, Inc. in 1991. It changed its name to GK Intelligent Systems, Inc. in 1994; and to M Power Entertainment, Inc. in 2005. Further, the company changed its name to eDOORWAYS Corporation in September 2007. eDOORWAYS Corporation is based in Houston, Texas.

EDWY News:

October 20 - eDoorways Invited to Demonstrate on a World Stage at the Ibero-American Science and Technology Education Center's XVII Annual General Assembly

Prominent International Organization ISTEC Has Asked eDoorways to Demonstrate Its Platform and Speak on the Advances Made in Education Through Its Intelligent Learning Solution, "LEARN"

eDoorways Corporation (OTC: EDWY) is scheduled to present at ISTEC's (Ibero-American Science and Technology Education Center) 17th annual General Assembly, held the week of October 26 - 30, 2009, on the Campus of the University of New Mexico (UNM) in Albuquerque, NM, USA. The theme for this year's General Assembly is, "Using Technology to enable Collaboration, and Collaboration to Advance Science and Technology."

Gary Kimmons, Chairman & CEO of eDoorways Corporation, said, "This is one of those rare opportunities. Where a growing company like eDoorways has the chance to get on the 'big stage' in front of groups like Sun Microsystems, Hewlett Packard, National Instruments, Institute of Electrical and Electronics Engineers, Charles Darwin Research Station and the World Bank, all members of ISTEC, mainly because we've been recognized for the possibilities we bring to society through our innovative platform, doorways and learning solutions."

ISTEC's board of directors extends this invitation at the behest of its founder Dr. Ramiro Jordan.

ISTEC, founded in 1990 as a spinoff of UNM, has become one of the largest non-profit consortia in the Americas dedicated to improving the quality of life through education throughout Latin America, Spain and Portugal. Harnessing the strength of its 20,000 faculty and staff members, ISTEC is able to deliver curricula on science, technology, engineering, math, R&D and entrepreneurship to 120 universities and 18 million online users throughout Latin America and other parts of the world.

"This year's theme for the General Assembly, 'Using Technology to Enable Collaboration and Collaboration to Advance Science and Technology' speaks directly to eDoorways' business," states Kimmons. "We are utilizing the web to foster collaboration between people. Whether it is matching a buyer and seller or creating educational opportunities through 'LEARN,' the foundation of eDoorways is the collaboration of people to achieve common goals with mutually rewarding outcomes in 'real-time.'"

Dr. Ramiro Jordan said, "ISTEC is dedicated to the improvement of international collaborations in science and technology and the development of human capital, the cornerstone of which is education. We see eDoorways as a powerful way to utilize the Internet in pursuit of our objectives. eDoorways has a platform that uses social networking in two areas of great interest to ISTEC. The first use is for social entrepreneurs, those people who are going to lead social progress in the region. The second is for commercial entrepreneurs, those who are going to start and grow the businesses of the 21st century that will create the jobs and other opportunities needed."

He adds, "In the area of education, being that the 'LEARN' doorway is premised on an already proven technology, it is expected that eDoorways will aid tremendously in our delivery of educational tools and courses to our users."

The City of Albuquerque and the Albuquerque Hispano Chamber of Commerce support the General Assembly event, linking eDoorways directly into the power source of another growing city.

Sources close to the company believe ISTEC to be vehicle for the advancement of education and development of generational wealth in the Americas and Iberia, which allows eDoorways great opportunity, especially where it concerns its second developing doorway, "LEARN." With an opportunity to grace the world stage, eDoorways expects even greater visibility for its "real-time" web 3.0 platform and "SOLVE" doorway.

ABOUT ISTEC

ISTEC is a non-profit organization comprised of educational, research, industrial, and multilateral organizations throughout the Americas and the Iberian Peninsula. The Consortium has been established to foster scientific, engineering, and technology education, joint international research and development efforts among its members, and to provide a cost-effective vehicle for the application and transfer of technology.

OPTIGENEX INCORPORATED (OTC: OPGX)

"Up 60.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/OPGX.php 

Optigenex inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11® (Formerly known as C-MED-100®) a patented compound as it core product. AC- 11® is the bioactive, water soluble form of the medicinal herb Uncaria tomentosa.

OPGX News:

October 21 - Optigenex Inc. Announces Supply And License Agreement With Suracell Inc. To Utilize The AC-11® Trademark And Technology For Oral Supplements In The United States, Canada And South Korea

Optigenex Inc. (OTC: OPGX) announced the signing of a Supply and Trademark License Agreement with Suracell Inc. to provide its patented ingredient AC-11® for use in a focused nutritional and age management dietary supplement program. The agreement coupled with Suracell's marketing plans will provide another platform to introduce Optigenex's technology under the registered trademark AC-11® to health conscious consumers in the United States, Canada and South Korea.

Beginning in January 2010, Suracell will be marketing a specific dietary supplement regimen. Participants will complete lifestyle questionnaires and will be asked to provide specimens for testing of key bio markers that will form the basis for a focused nutritional supplement program utilizing the diverse line of Suracell formulated products with AC-11®.

All-natural, herbal-extracted and patented AC-11® is marketed by over 100 manufacturers and marketing companies in Japan, Europe, the Middle East, the United States and Canada in a variety of anti-aging cosmetic, dietary supplement and advanced DNA care products.

Daniel Zwiren, president and CEO of Optigenex Inc. said, "We are excited to add Suracell to our family of customers. We believe Suracell's scientifically validated formulas are an ideal fit for the unique properties of AC-11®, including natural DNA repair, immune enhancement and inhibition of pro-inflammatory agents. The licensing relationship we are entering into today will allow both companies to expand significantly their respective businesses and market penetration.

A Suracell spokesperson added, "The addition of AC -11® to the proprietary customized Suracell formulations gives us a product line unparalleled in its potential benefits to its customers. The evolving science surrounding AC 11® promises a very exciting future for our product offerings.

ABOUT SURACELL INC.

Suracell Inc. provides personal genetic health programs formulated to measure, assess treat and monitor the body's individual genetic needs. The testing and analysis programs are designed to pinpoint deficiencies and damage in an individual's DNA and provide personalized recommended protocols consisting of specially formulated nutraceuticals and positive lifestyle choices.

ACCREDITED BUSINESS CONSOLIDATORS CORP. (OTC: IOVE)

"Up 23.26% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/IOVE.php

Accredited Business Consolidators Corp., formerly known as the Italian Oven, is a diversified holding corporation. Visit www.accreditedbiz.com (under construction) for information on its affiliated companies. The total number of common shares outstanding is 436,399,500. 328,018,200 shares are in the public float and on hand with CEDE & Co., 70,546,600 shares are restricted in certificate form, and 37,834,700 shares are unrestricted but in certificate form. There will be no increase in shares until at least April 2010.

IOVE News:

October 20 - Accredited Business Consolidators Corp. to Divest Richwood Eco Ventures Inc. and to Issue Dividend

Accredited Business Consolidators Corp., trading as Italian Oven, Inc. (OTC: IOVE), issued a resolution to divest the Company's Richwood Eco Ventures Inc. subsidiary.

IOVE will begin the paperwork to obtain a CUSIP for the subsidiary and will subsequently issue a one for one dividend to present shareholders of IOVE. That is, for every share of IOVE, one share of Richwood Eco Ventures would be issued to the IOVE shareholder. The ex date will be set in the next three to six weeks. Richwood Eco Ventures maintains a share structure of 999,999,999 authorized shares.

After the issuance of the dividend and the close of the fiscal year, the Company will take the appropriate action necessary to have the financial statements of Richwood Eco Ventures Inc. audited and to register the securities in question with the Securities and Exchange Commission. Once registered, the Company will attempt to secure a market maker for the registered securities so that a trading symbol may be obtained from FINRA.

This divesture is mutually exclusive from the planned issuance of Accredited Consolidators Europe PLC shares to IOVE common shareholders at the rate of 1 ACE PLC share for every 250 IOVE shares. (There will only be 5,000,000 shares of ACE PLC.)

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks has been compensated ten million free trading shares from a non-controlling third Party (Microcap Management) for DVME advertising and promotional services.